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Accuracy of Blood Group 
Typing in the Management and 
Prevention of Alloimmunization
Emilia Sippert, Evgeniya Volkova and Maria Rios
Abstract
Blood transfusion is an effective therapeutic approach for several hematologi-
cal conditions including sickle cell disease (SCD), thalassaemia, myelodysplastic 
syndrome (MDS), and autoimmune hemolytic anemia. It is also often indicated for 
transplantation and for patients receiving medical treatments for cancer. However, 
transfusion treatment can lead to the red blood cell (RBC) alloimmunization 
when an incompatible antigen is inadvertently present in the transfused blood. 
Alloantibodies can cause RBC destruction and many other complications defeating 
the purpose of the treatment. The risk of development of multiple alloantibodies 
increases with the frequency of transfusions in transfusion-dependent patients and 
can be mitigated by transfusing blood type negative for multiple antigens to prevent 
hemolysis. This chapter discusses the transfusion’s risk of RBC alloimmunization as 
an adverse event; consequences of alloimmunization in patients’ care; approaches to 
prevent and/or mitigate alloimmunization and enhance transfusion efficacy; appli-
cation of RBC genotyping to supplement serology for preventing alloimmunization. 
The currently available techniques for RBC genotyping and the importance of 
reference reagents for determining the genotyping accuracy will also be discussed.
Keywords: blood transfusion, RBC alloimmunization, blood groups,  
blood group genotyping, reference materials
1. Introduction
Blood transfusion saves lives in trauma situations and serves as a unique thera-
peutic treatment of various hematologic disorders where patients require lifelong 
regular transfusions to survive. However, in contrast to therapeutic drugs, blood 
cannot be manufactured and tested for quality control of purity, potency, and 
efficacy. Instead, each donation is a unique batch, most often single use, for which 
all characterization and quality assessment need to be performed individually even 
if several units are used in a single treatment. Since blood is a biological product, 
safety assessment must be done at multiple levels, including donor screening, blood 
collection, testing for infectious agents, blood cell typing and labeling. Checkpoints 
and quality control are also required at the time of transfusion to avoid human 
error and to guarantee that the right blood goes to the right person. Each step has its 
own characteristics and challenges. Screening involves the review of donor history 
that allows assessment for safety; requirements that need to be followed for blood 
collection to assure proper timing, storage, and processing so that the quality of the 
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product is not compromised; testing for infectious agents ensures a second layer of 
screening for pathogens that could be transmitted to the patient with an infected 
blood unit; testing for blood cell typing helps to avoid improper usage of the 
product since non-compatible blood can produce serious consequences and even 
fatalities; lastly, the transfusion process itself requires strict checkpoints to prevent 
the use of an incompatible unit in a given patient.
The scope of this chapter focuses on blood group typing  and approaches to 
achieve better management and prevention of alloimmunization. We will provide 
an overview on the following topics: blood transfusion and risk of RBC alloim-
munization; approaches for prevention of alloimmunization and improvement of 
transfusion therapy; serology and molecular typing methods and their use for RBC 
matching; current technologies for RBC genotyping; and standards for red cell 
antigens typing including scope, importance, and description of reference reagents 
available for use.
2. Blood transfusion and risk of RBC alloimmunization
RBC transfusion is used for therapeutic treatment of various hematologic disor-
ders including SCD, thalassaemia, MDS, autoimmune hemolytic anemia, and others. 
Management of patients may require lifelong regular transfusions for treatment of 
symptomatic anemia and prevention of disease complications. Although transfusion 
safety and donor-patient matching have improved over the years, RBC alloimmuni-
zation, transmission of infections, and iron overload are still a concern [1].
RBC alloimmunization is a serious adverse event of transfusions and can cause 
further clinical problems in the patients including worsening of anemia, develop-
ment of autoantibodies, acute or delayed hemolytic transfusion reactions (DHTR), 
bystander hemolysis, organ failure, and cause serious complications during preg-
nancies. Frequent transfusions can lead to the production of multiple alloantibod-
ies, which is often associated with autoantibodies requiring extensive serological 
workups and additional transfusions for proper treatment, increasing time and 
resources to find compatible RBC units [2].
Antibodies against ABO blood group antigens are naturally produced, IgM class, 
and are capable of rapid induction of intravascular destruction of RBCs by comple-
ment-mediated mechanism. Clinical outcome of a patient transfused with incom-
patible ABO blood can vary from no adverse effects to permanent organ damage 
and death depending on the volume of ABO-incompatible RBC transfused. As for 
non-ABO blood groups, clinically significant antibodies against non-ABO antigens 
are from IgG class and rarely activate complement. Instead, they cause DHTR or 
hemolytic disease of fetus and newborn (HDFN) by extravascular destruction of 
RBCs marked with IgG [3]. DHTR has been ranked as second or third most com-
monly reported cause of fatal transfusion reactions secondary to non-ABO antibod-
ies in many countries including the United States [4–8]. However, experts believe 
that DHTR has been under-recognized or under-reported to biovigilance agencies 
and FDA, possibly because the reactions can be obscured by underlying disease 
(liver disease, massive trauma, and SCD), lack of knowledge among clinicians 
regarding the reactions, or lack of knowledge regarding the mechanism of report-
ing [7].
Reported RBC alloimmunization rates have considerable variations depending 
on the population and disease studied [9]. The rates are estimated between 1 and 
3% in patients that receive episodic transfusions, while for patients who receive 
chronic blood transfusions like patients with SCD and MDS, rates vary between 8 
and 76% [9–12]. Although the most commonly observed alloantibodies of clinical 
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relevance are against antigens belonging to RH (D, C, c, E, e), KEL (K, k, Jsa, Kpa), 
JK (Jka, Jkb), FY (Fya, Fyb), and MNS (M, S, s) blood group systems [9], alloanti-
bodies against Rh variants [13–15] and other rare blood group phenotypes have also 
been implicated in shortened survival of transfused RBCs by causing DHTR [13, 16] 
or HDFN [17]. In addition, some antibodies only have occasional reports of being 
clinically significant, that is, anti-Yta, -Ge, and -N or have no clinical significance 
unless reactive at 37°C, that is, anti-Lea, -Leb, -M, -N, -P1, -Lub, -A1, and -Bg [18].
The development of RBC antibodies is influenced by many factors including 
recipient’s gender, age, and underlying disease. The diversity of the blood group 
antigen expression among the donor and patient populations contribute substan-
tially to the high alloimmunization rates [15]. Other factors that might be associated 
with alloimmunization risk have been actively explored in seeking novel strategies 
for prevention of alloimmunization [19]. Studies in both animal models and SCD 
patients have reported that inflammation is associated with higher likelihood of 
alloimmunization and it is suggested that the extent of the alloimmune response is 
higher when RBCs are transfused in the presence of an inflammatory signal [19–23]. 
Several studies have suggested that genetic variation in immune-related genes such 
as TNFA, IL1B, CTL4, CD81, TRIM21, TLR1/TANK, MALT1 [24–28], and human 
leukocyte antigens (HLA) [24, 29] might be associated with susceptibility to or 
protection from alloimmunization. Importance of unit’s age and blood product 
modifications like leukoreduction or irradiation has also been investigated but their 
impact remains unclear.
3.  Prevention of alloimmunization and improvement of transfusion 
therapy
Prevention of alloimmunization is desirable for any blood transfusion; however, 
for patients not previously transfused or only having episodic blood transfusions, 
matching for all clinically significant antigens is not of great concern, but can 
result in alloimmunization against non-matched antigens. For patients previously 
transfused, particularly transfusion-dependent patients, the alloimmunization risk 
is higher and management of alloimmunized patients is of greater concern. Their 
alloimmunization status, including antigens of low clinical significance, is a critical 
part of their clinical history that may enable health care providers to take measures 
to prevent further alloimmunization.
As of May 2019, the International Society of Blood Transfusion (ISBT) rec-
ognizes 36 blood group systems. Of the 360 identified antigens, 322 have been 
assigned to a specific blood group system. These antigens have variable immunoge-
nicity and not all blood group antigens are involved with the production of clinically 
significant antibodies after blood transfusion or pregnancy. Ideally, every blood 
transfusion should be compatible for the most clinically significant antigens in the 
RH (D, C, E, c, e), KEL (K), FY (Fya, Fyb), JK (Jka, Jkb), and the MNS (S, s) systems 
to prevent alloimmunization; however, the standard pre-transfusion cross-match-
ing is only performed for ABO blood group and the Rh(D) antigen; ABO matching 
is performed to avoid acute hemolytic transfusion reactions caused by natural IgM 
antibodies against ABO antigens, and Rh(D) matching is performed because of the 
high immunogenicity of the Rh(D), which is implicated in DHTR and HDFN.
Currently, recommendations for partial and extended donor unit/patient match-
ing are limited to specific groups including [1] patients on long-term transfusion 
protocol (i.e. SCD, MSD, thalassaemia, and aplastic anemia), [2] patients who have 
developed alloantibodies, and [3] patients with warm autoimmune hemolytic anemia.
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Verification of compatibility for Rh (D, E, C, c, e) and K, which are the most 
frequent antigens involved in alloimmunization, is considered partial matching. 
Extended matching should include at least RH (D, C, E, c, e), KEL (K), FY (Fya, 
Fyb), JK (Jka, Jkb), MNS (S, s) and, if available, additional antigens.
3.1 Serology typing
Knowledge of the role of blood groups with their antigens and variants in allo-
immunization was pivotal for the development of transfusion practices and medical 
interventions that require blood transfusion such as trauma, hematological diseases 
(e.g. SCD, MDS, thalassaemia, and aplastic anemia) and later for transplantation 
and cancer treatment.
Serology has been considered the gold standard technique for blood group typ-
ing for a long time. Serological methods detect the antigen expressed on the red cell 
using specific antibodies and can be carried out manually or by automated plat-
forms. Typing of blood group antigens using this method is easy, fast, reliable, and 
accurate for most of the antigens. However, serology has limitations, some of which 
cannot be overcome when it is used as a standalone testing platform (Table 1). 
Scarcity of serological reagents for some blood group systems for which there is 
no monoclonal antibody available is a major limitation. In addition, human serum 
samples from different donors vary in reactivity, which is an issue when a nearly 
exhausted batch of reagent needs to be replaced. This is especially problematic 
when an alloantibody for that antigen is suspected to be causing adverse events after 
transfusion. In those circumstances, molecular methods can be used as an alterna-
tive or as a complementary test for identification of genes associated with the blood 
group antigens expression and prediction of antigenic profile (see Table 1).
3.2 Molecular typing
The identification of genes that encode proteins carrying blood group antigens 
and the molecular polymorphisms that result in distinct antigenicity of these 
proteins is possible using molecular typing methods, which facilitate blood typing 
Serology limitation Genotyping application
No available antisera, weak or limited 
antisera (i.e. Doa, Dob, Jsa, Jsb, Kpa, Kpb, V 
and VS)
Blood group typing can be easily performed by single PCR 
and/or high throughput platform
Mixed field caused by the presence of 
donor’s RBCs in patient’s sample (i.e. 
patients with recent blood transfusions)
Presence of interfering antibodies (i.e. 
autoantibodies, multiple antibodies, 
antibodies against high prevalence antigens)
Genotyping is performed with extracted DNA from 
nucleated cells (e.g. leukocytes, epithelial). The presence of 
donor’s RBCs or interfering antibodies in patient’s sample 
does not interfere with the results
Presence of variant antigens (i.e. hybrid 
RH types, FY silencing mutations, MNS 
hybrids)
Detection of genes and molecular mechanisms associated 
with variant antigen expression
Detection of blood type of fetus at risk of 
HDFN without invasive procedure
Detection of blood type and zygosity on DNA extracted from 
maternal plasma
Mass screening for antigen-negative and 
rare RBC phenotypes
Use of high throughput platforms for donor screening allows 
mass scale typing and creation of databases
Table 1. 
Benefits of genotyping over serology.
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resolution in complex cases and overcome limitations of serological techniques 
when dealing with alloimmunized and multitransfused patients. In addition, 
molecular techniques have allowed identification of genes encoding clinically 
relevant antigens for which serological reagents are not available (see Table 1). In 
those instances, genotyping is critical to resolve clinical challenges.
Blood group genotyping is performed to predict blood group antigens by iden-
tifying specific polymorphisms associated with the expression of an antigen. Most 
variations in the blood group antigens are linked to point mutations, but for some, 
other molecular mechanisms are responsible, such as deletion or insertion of a gene, an 
exon or a nucleotide sequence (i.e. ABO, RH, and DO blood group systems), sequence 
duplication, (i.e. RHD gene and GE blood group system), nonsense mutation (i.e. RHD 
gene), and hybrid genes (i.e. RH, MNS, ABO, and CH/RG blood group systems) [30].
In contrast to serology, molecular tests are performed on DNA obtained from 
nucleated cells and are not affected by the presence of donor’s red cells in patient’s 
sample, which is a common occurrence in samples of patients with recent/multiple 
blood transfusions. Thus, RBC genotyping can resolve blood group typing discrep-
ancies in multitransfused patients presenting with mixed field reactions, alloanti-
bodies, or autoantibodies (Table 1). Also, blood group genotyping can substantially 
help patients who were not previously phenotyped and need regular transfusions by 
facilitating management of these patients and preventing alloimmunization [31].
Studies comparing serology and genotyping in multitransfused population such 
as patients with thalassaemia and SCD have shown that genotyping is superior to 
serology for resolving discrepancies [31–35]. Use of genotyped matched units has 
been shown to decrease alloimmunization rates [36], increase hemoglobin levels 
and in vivo RBC survival, and diminish frequency of transfusions [37–39].
3.3 Sickle cell disease
SCD is the most common congenital red blood cell disorder affecting millions of 
people worldwide with high mortality and morbidity rates [40]. It is considered a 
major public health issue by the WHO. Characterized by an abnormal synthesis of 
hemoglobin, this genetic trait is most common among people of African ancestry. 
Abnormal hemoglobin carried in red cells causes these cells to sickle (thus the name 
SCD), which as early symptoms produces swelling of the hands and feet, anemia, 
fatigue, and jaundice. Long-term effects of the disease include serious damage in 
spleen, brain, eyes, lungs, liver, heart, kidneys, bones, and/or skin that can accumu-
late over a person’s lifetime. Patients can survive beyond their 50s, and most fatali-
ties are not associated with chronic organ failure but occur due to an acute episode 
of one of the SCD complications. SCD can be cured by bone marrow transplanta-
tion, but only a few patients get transplant.
Blood transfusion therapy is part of treatment for SCD patients and it is mainly 
indicated for prevention of stroke and vaso-occlusive crisis. However, transfusion 
benefits are limited upon development of alloantibodies, a common adverse event 
of transfusion. The high incidence of RBC alloimmunization in SCD is multifacto-
rial, but lack of blood group compatibility between donor and recipient is a key 
factor. This is more evident in countries where donors’ and patients’ ethnicities 
significantly diverge, that is, in North America, where blood donors are mostly 
Caucasians while SCD patients are predominantly of African descent; thus, SCD 
patients are frequently exposed to foreign antigens and, consequently, have higher 
risk of developing multiple alloantibodies.
Transfusion protocols for management of SCD and prevention of alloimmu-
nization vary among the hospitals and transfusion services. In many centers that 
provide care to SCD patients, transfusions are phenotypically matched for RH  
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(D, C/c, E/e) and K [41], while others provide extended matching including RH (D, 
C, c, E, e), KEL (K, k), FY (Fya, Fyb), JK (Jka, Jkb), and MNS (S, s) in addition to 
the standard ABO and Rh(D). Less frequently, extended matching is performed by 
genotyping [36]. However, a wide range of institutions do not request phenotypi-
cally matched RBC units until the patient has produced an alloantibody [42].
It has been reported that antibodies against Rh antigens are the most frequently 
identified antibodies in multitransfused SCD patients despite transfusion from Rh 
phenotype matched donors [15]. The main reason for that is the high frequency 
of Rh variants in people of African descent. It has been reported that 90% of SCD 
patients and donors of African ancestry have at least one variant RHD or RHCE 
allele [15, 43]. The term “variant” is used when RHD and/or RHCE genes are carry-
ing genetic alterations that may affect the RhD and RhCe protein expression. Variant 
alleles can encode weak and/or altered antigens and serological methods are limited 
in which variant Rh antigens can be identified and might not be reliable [44, 45].
The prophylactic RBC matching performed by serology typing, before expo-
sure to RBC transfusions, can decrease transfusion complications in SCD patients 
substantially, but does not eliminate the occurrence of alloimmunization against 
Rh variants and other non-matched antigens that can cause DHTR [41]. Currently 
available molecular typing methods can predict several blood group antigens allow-
ing a more precise RBC matching and can support transfusion decision-making. 
RHD and RHCE genotype matching particularly benefits SCD patients carrying Rh 
variants. For instance, SCD patients presenting D+ or e+ phenotype can make allo-
antibodies to these antigens despite receiving Rh phenotyped matching RBCs. The 
molecular analysis in such individuals may identify polymorphisms in RH genes 
responsible for the phenotypic alteration, confirming the alloimmune status of the 
antibody. In such cases, provision of RH genotype matched units or units negative 
for the specific antigen would be recommended, because the antibodies produced 
may be clinically relevant [13, 15].
An additional benefit of blood group genotyping on transfusion management of 
SCD patients is the capability of identifying silence mutations like −67T>C in the 
ACKR1 gene (Duffy gene). Patients carrying the mutation can receive Fy(b+) units, 
because the mutation only abolishes expression of Fy(b) on red cells but not in 
other tissues. The detection of this mutation avoids unnecessary use of Fy(b−) and 
increases the chances to find compatible units available even for highly restrictive 
matching.
Extended genotyping including Dombrock: Doa, Dob, Joa, Hy; Kell: Kpa, Kpb, Jsa, 
Jsb; Rh: V, VS; Colton: Coa, Cob; Cartwright: Yta, Ytb; Lutheran: Lua, Lub; Diego: Dia, 
Dib; and Scianna: Sc1, Sc2 may help prevent development of clinically significant 
antibodies that can be potentially life-threatening.
3.4 Thalassaemia
Thalassaemia is an inherited blood disorder associated with a mutation in one 
of the genes involved in hemoglobin production resulting in abnormal form or an 
inadequate amount of hemoglobin. RBCs carrying abnormal hemoglobin do not 
function properly and are destroyed in large numbers leading to anemia. People 
with thalassaemia may have mild or severe anemia depending on the type of 
thalassaemia. Severe anemia requires regular blood transfusions to maintain the 
hemoglobin and RBCs levels, and to suppress the ineffective erythropoiesis but can 
lead to alloimmunization.
The prevalence of alloimmunization in patients with thalassaemia varies among 
geographical locations and may be related to the heterogeneity of population, trans-
fusion exposure frequency, patients age, antigen matching policy, recipient related 
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factors, and other factors [46]. The most common alloantibodies reported in these 
patients are against RH (primarily anti-E and anti-C) and K, followed by antigens 
of the FY, JK, MNS, and other blood group systems. Development of autoantibodies 
is also commonly observed in these patients. A policy for RH and KEL matching 
been introduced worldwide and its effectiveness has been demonstrated by the 
decreasing rates of alloantibody and autoantibody formation [46–48].
The Thalassaemia International Federation guidelines for transfusion-dependent 
thalassaemia published in 2014 recommends that all patients should receive pro-
phylactic ABO, RH (D, C, c, E, e), and KEL (K) matched transfusions identified 
either with serology or genotyping. In addition, it is indicated that antigen typing 
should be performed using molecular rather than serologic testing if the patient had 
received transfusions previously [49]. However, surveys have reported that there 
is still a lack of adherence to recommendations and a large variation in transfu-
sion practices for thalassaemia and SCD patients among the health care systems 
[42]. Some of the challenges for transfusion centers include difficulty in obtaining 
a reliable antibody and transfusion history and the lack of standards regarding 
procedures for phenotyping and transfusion matching [42].
Molecular typing has been introduced in several centers to confirm extended 
blood group profiles obtained through serological methods, however, it is not 
routine yet [31, 32, 42]. This approach is particularly important for thalassaemia 
patients because these patients are transfusion-dependent and, in many circum-
stances, might have received transfusions at hospitals with different transfusion 
matching policies, therefore the phenotyping might not be reliable.
3.5 Rare type blood donor selection
Alloimmunized patients require transfusion of RBCs that are negative for a 
particular antigen. Historically, serology methods, which are labor-intensive and 
time-consuming, have been used to screen for antigen-negative units. However, 
the standard practice is likely to change with the high-throughput platforms for 
blood group genotyping being approved by regulatory bodies and becoming more 
widely used. High-throughput platforms allow identification of a higher number of 
antigens compared with serology, increasing the availability of blood characterized 
for clinically relevant antigens.
The implementation of RBC mass scale genotyping for donor screening has started 
in blood centers, especially in large collecting facilities [50–53]. The successful estab-
lishment of a blood group genotype database has already been accomplished aiming 
to fulfill antigen-negative requests, especially for SCD patients receiving regular 
transfusions, and to create an inventory of frozen red cell units with rare blood types 
[51]. The refereed database comprises 43,066 non-Caucasian blood donors genotyped 
for 32 single nucleotide polymorphisms, related to the expression of 42 blood group 
antigens. The report showed that within 4 years of starting RBC genotyping, the 
blood group antigen database generated on blood donors was fivefold larger than that 
obtained by serology methods over 30 years. In addition, most antigen-negative units 
requests to that center were met using exclusively the genotyping database.
Strategies for finding units to fulfill transfusion requests for SCD patients 
have included RBC genotyping of non-Caucasian blood donors and donors with 
altered Rh antigen expression [54, 55]. The genotyping selection of donors with a 
genetic background similar to that of SCD patients’ increases the chances of finding 
compatible blood for these patients, including RH-genotype matching. However, 
the low percentage of blood donors with African ethnic background combined with 
the cost of genotyping are limiting factors for widespread use of extended RBC 
genotyping matching strategy.
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4. Molecular testing: current technologies
Polymerase chain reaction (PCR) and further advancements in molecular meth-
ods such as DNA sequencing and recombinant DNA technology allowed elucidation 
of the molecular basis of most of the blood group antigens and subsequent use of 
molecular techniques employed for blood group genotyping initially as in-house 
assays or laboratory developed tests (LDT) and later as commercially available assays.
While molecular basis for many of the blood group systems is relatively straight-
forward, with two antithetical alleles differing by a single nucleotide polymorphism 
(SNP) and responsible for one of the two possible phenotypes, some blood group 
systems are very complex. RH blood group system has over 50 antigens described 
Name/manufacturer Principle Number of polymorphisms/antigens 
identified
Immucor PreciseType 
HEA Molecular BeadChip 
Test#,$ [56]
BioArray Solutions
Multiplex PCR followed by 
hybridization of amplified DNA 
to probes attached to spectrally 
distinguishable beads and 
elongation
24 polymorphisms associated with 38 
antigens plus phenotypic variants and 
Hemoglobin S
BioArray RHCE and RHD 
BeadChip$ [57]
BioArray Solutions
Multiplex PCR followed by 
hybridization of amplified DNA 
to probes attached to spectrally 
distinguishable beads and 
elongation
35+ RHCE variants; 80+ RHD variants
ID CORE XT#,$ [58]
Progenika Biopharma
Multiplex biotinylating PCR 
followed by hybridization 
to probes on color-coded 
microspheres
29 polymorphisms associated with 37 
antigens and phenotypic variants
ID RHD XT$ [59]
Progenika Biopharma
Multiplex biotinylating PCR 
followed by hybridization to 
probes coupled to color-coded 
microspheres
6 RHD variants and HPA-1
Hemo ID DQS Panel$ 
[60, 61]
Agena Bioscience
Multiplex end-point PCR and 
single base primer extension
101 antigens associated with 
16 systems, and 23 platelet and 
neutrophil antigens, in modules
HIFI Blood 96$ [62]
AXO Science
Automated multiplex PCR and 
microarray-based assay
15 polymorphisms associated with 24 
antigens
RBC-FluoGene vERYfy 
eXtend$ [63]
inno-train diagnostik 
GMBH
Automated TaqMan-based assay 70 antigens and phenotypic variants 
associated with 12 systems
RBC-ReadyGene$ [64]
inno-train diagnostik 
GMBH
PCR-SSP-based assay 16 modules encompassing antigens 
and variant phenotypes within 13 
systems
TaqMan genotyping on 
OpenArray [65, 66]
BioTrove
Nanofluidic TaqMan assays 
performed in OpenArray plates
16, 32 or 64 assays (custom designed)
Pre-designed TaqMan 
assays
Thermo Fisher Scientific
Real-time allelic discrimination 
PCR
Polymorphisms associated with 8 
systems
#FDA approved.
$CE mark certification.
Table 2. 
Commercial solutions available for blood group genotyping.
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to date, more than 500 alleles, and 2 highly homologous genes that, in addition to 
SNPs, insertions, and deletions, may have hybrid configurations. Other systems 
with more than 50 alleles currently identified include MNS, Diego, and Kell. 
Genotyping strategies are often based on a SNP altering a restriction site or punc-
tuating otherwise perfectly matched sequence for primers or probe annealing site. 
These approaches may be suboptimal for designing genotyping assays of complex 
systems and fail to reveal rare variants. Next generation sequencing (NGS) is the 
only method that can reliably detect the exact genetic composition of the site mak-
ing it possible to predict the phenotype.
Name Principle Number of polymorphisms/
antigens identified
Multiplex PCR-single-strand 
conformation polymorphism 
(SSCP) analysis [67]
Denaturation of PCR product followed by 
fragment analysis in polyacrylamide gel
9 polymorphisms associated with 
1 blood group
PCR-RFLP [68–74] Amplification of target sequence followed 
by enzyme digestion (PCR-RFLP)
Varies
PCR-SSP [75–77] Amplification of single alleles using 
allele-specific primers
Singleplex or multiplex
Multiplex-PCR [78, 79] Amplification with multiple primers 
followed by gel electrophoresis
Polymorphisms associated with 6 
exons of RHD
Quantitative multiplex 
PCR of short fluorescent 
fragments (QMPSF) [80]
Amplification of multiple targets using 
both specific and universal-FAM-labeled 
primers detected by electrophoresis
10 exons of both RHD and RHCE
Denaturing high-performance 
liquid chromatography 
(DHPLC) analysis [81]
Amplification followed by enrichment 
with a known sample and DHPLC 
analysis
Entire RHD gene
Multiplex ligation-dependent 
probe amplification (MLPA) 
[82]
MLPA probes hybridized to DNA 
target sequence followed by fragment 
amplification and detection
48 alleles encoding blood group 
antigens and 112 variant alleles of 
18 blood groups
GenomeLab  
SNPStream [83]
Multiplex PCR followed by single-
nucleotide extension and hybridization to 
complementary oligonucleotides
12 polymorphisms associated 
with 6 blood groups and platelet 
antigens
High-resolution melting 
analysis [84, 85]
PCR with gene-specific primers and 
probes followed by melting curve analysis
Various—customized
Single nucleotide primer 
extension minisequencing 
assay (SNaPshot) [86]
Multiplex PCR followed by SNaPshot 
reaction and fragment analysis
Various—customized
Microsphere-based array [87] Multiplex PCR followed by hybridization 
to probes coupled to fluorescent 
microspheres
8 polymorphisms associated with 
6 blood groups
Multiplex PCR and DNA 
microarray hybridization [88]
Chimeric primers (specific-universal 
tag) are used along with fluorescent-label 
universal primers followed by products 
hybridization to a DNA array
Gene fragments of 19 different 
RBC and platelets antigen 
systems
Sanger sequencing [89] Classical DNA sequencing of single 
fragment using dye terminators
Various—customized
Next generation sequencing 
(NGS) [90]
Sequencing of entire genome or specific 
regions. Millions of small fragments of 
DNA are simultaneously sequenced
Various—customized
Table 3. 
Other techniques developed for blood group genotyping.
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Genotyping methodologies vary widely and include labor-intensive techniques 
that are best suited to test individual samples for limited number of polymorphisms 
(i.e. PCR-RFLP and PCR-SSP), high-throughput commercial kits that are relatively 
easy to use (i.e. real-time PCR and arrays), and methods that require specialized 
equipment to differentiate between alleles in multiple blood group systems at once 
(i.e. NGS). Most of assays described to date rely on enzyme-mediated DNA ampli-
fication at some point in their workflow and on sequence-specific primers or probes 
(Tables 2 and 3).
At the time of this writing, several platforms have been commercialized, 
but only two commercial assays have been approved by the US FDA. Immucor 
PreciseType by BioArray Solutions was approved in May 2014 and ID CORE XT 
manufactured by Progenika Biopharma was approved in October 2018. Due to 
less stringent requirements to obtain the European Conformity (CE mark), this 
certification has been granted to most of the commercial devices described here 
(see Table 2). Commercial assays not approved by the FDA can be labeled and 
utilized for research or investigational use only. Some commercial platforms (such 
as OpenArray or GenomeLab SNPStream) are used to run LDT assays to increase 
the throughput (Table 3).
5. Molecular testing: standards for RBC antigens
The use of molecular typing for characterization of blood group genes has been 
steadily increasing in the last few decades due to the transfusion benefits for the 
patients, technological advances in molecular techniques, and expanding availabil-
ity of mass-scale genotyping. While blood group genotyping is becoming increas-
ingly used, typing errors have been documented indicating the need for quality 
control.
International Workshops on Molecular Blood Group Genotyping have reported 
discrepancies between laboratories studying the same samples indicating that there 
is room for improvement [91, 92]. As a genotyping test may only be done once 
in a person’s lifetime, errors can have serious consequences. A major challenge in 
performing routine RBC genotyping is controlling for process variability of molecu-
lar assays that arises due to scarcity of reference materials. This limitation has been 
circumvented by using clinical specimen leftovers from previous testing, which 
lack proper characterization. Reference materials are critical for the development 
and manufacture of testing kits, for test calibration and for monitoring of assay 
performance.
Recommendations on which targets and recommended controls to use for 
prediction of RBC antigens have been published by international societies offering 
proficiency test programs such as INSTAND [93], The Consortium for Blood Group 
Genes (CBGG) [94], College of American Pathologists (CAP), and International 
Society of Blood Transfusion (ISBT) [91, 92] and also by The American Association 
of Blood Banks (AABB) [95] whose focus is on creating guidelines for AABB 
accreditation aiming to certify laboratories that perform molecular testing for red 
cell, platelet, and neutrophil antigens.
Molecular testing laboratories participate in accreditation programs to validate 
their activities. In the US, the requirements for AABB accreditation are described 
in the 4th edition of standards for molecular testing for red cell, platelet, and 
neutrophil antigens (updated in October 2018) [95]. According to the document, 
“laboratories shall use appropriate reference DNA to validate and control the 
reported test” and further, “the reference DNA needs to contain the target poly-
morphisms reported by the laboratory”. The same publication lists the blood group 
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alleles within 17 blood group systems that should be included in the reference DNA 
materials by the lab seeking to meet the minimum requirements for accreditation.
Various preparations have been used as controls to monitor performance of 
blood group genotyping assays, including synthetic DNA (such as PCR prod-
ucts, plasmid-cloned PCR products) and genetic material from human samples 
col¬lected and characterized for that purpose following standard guidelines [96]. 
PCR products and plasmid-cloned PCR products are simple and easy to produce 
and use as controls for SNPs, but they lack the genomic complexity of human 
sample and do not represent the clinical analyte (genomic DNA); moreover, the 
synthetic material can be a source of contamination for the laboratory if not 
carefully handled and well diluted. Although well-characterized human specimens 
are the best representation of clinical samples, they are of limited source and the 
replenishment may not come from the same donor. The alternative to overcome 
source limitation is to transform human cells into immortalized cell lines and use 
those for characterization and formulation of reference reagents. This approach has 
been successfully used to produce reference DNA using B-lymphoblastoid cell lines 
(B-LCLs), which are an appropriate representation of the genetic material of the 
donor [97].
B-LCLs can be generated by Epstein Barr Virus (EBV) infection of peripheral 
mononuclear cells from genetically characterized donors carrying specific blood 
group antigens and variants. The infection leads to proliferation and subsequent 
cell immortalization, providing an unlimited source of donor’s genomic DNA. Once 
the B-LCLs are established, master and working cell banks are maintained in liquid 
nitrogen to ensure long-term survival of the cell line and continuous supply of 
the DNA. To produce the DNA reagent, B-LCLs from the working cell banks are 
expanded for bulk DNA extraction and subsequent DNA lyophilization. Tests on 
the lyophilized reagents are performed for assessment of their stability under accel-
erated degradation conditions and under normal conditions over longer periods of 
time as long-term stability. The material must be validated via collaborative studies 
with laboratories that routinely perform molecular blood typing.
The first DNA reference reagents for blood group genotyping developed 
using B-LCLs were produced in 2013 by the National Institute for Biological 
Standards and Control (NIBSC) and serve as World Health Organization (WHO) 
International Reference Reagents (IRR) for common blood group alleles found in 
ancestral Caucasians and Black African populations. The panel includes four DNA 
samples covering the most clinically important homozygous and heterozygous 
genotypes within RH, FY, KEL, JK, DO, and MNS blood group systems (Table 4). 
The material was validated in an international collaborative study by PCR-ASP or 
PCR-SSP, PCR-RFLP, Multiplex SSP assays, real-time PCR, Immucor Beadchip 
array, Progenika BLOODchip array, Luminex array, and 5′ Nuclease assay [98].
Additional cell lines were produced by CBER-FDA for use as source of genomic 
DNA for development of reference reagents to expand the number of red cell blood 
group polymorphisms represented in the first WHO IRR from 2013 for blood group 
genotyping. The CBER reference panel consists of 18 members, covering genotypes 
associated with 40 polymorphisms within 17 blood group systems, including alleles 
present in the existing WHO IRR-2013 except for RHD*ψ (Table 4). The CBER 
panel was also characterized and validated for additional genotypes belonging to 
systems already included in the WHO IRR-2013 (RH, KEL, FY, JK, DO, and MNS) 
(Table 4), and for additional systems only represented in CBER panel (ABO, LU, 
DI, YT, SC, CO, LW, CR, KN, IN, and OK) (Table 5) [89].
Participants in the international collaborative study to validate the CBER panel 
used traditional molecular techniques and additional genotyping techniques not 
available at the time of the first WHO IRR production. The most common methods 
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Blood group system WHO IRR [98] CBER RR [89]
Rh RHD positive (zygosity not determined) RHD*01/RHD*01 (RHD homozygous)
RHD*01/RHD*01N.01 (RHD hemizygous)
RHD*01 N.01/RHD*01 N.01 RHD*01 N.01/RHD*01N.01 (homozygous 
RHD deletion)
RHD*01 N.01/RHD*ψ
RHCE*C/RHCE*c RHCE*C/RHCE*c (307T/C; 109 bp intron 
2 ins present)
RHCE*C/RHCE*C RHCE*C/RHCE*C (307T/T; 109 bp intron 
2 ins present)
RHCE*c/RHCE*c RHCE*c/RHCE*c (307C/C; 109 bp intron 
2 ins absent)
RHCE*E/RHCE*e RHCE*E/RHCE*e (676C/G)
RHCE*e/RHCE*e RHCE*e/RHCE*e (676G/G)
Additional polymorphisms:
RHCE c. 122A>G (genotypes A/A; A/G)
RHCE c. 106G>A (genotype G/G)
RHCE c. 733C>G (genotype G/C; G/G; 
C/C)
RHCE c. 1006G>T (genotype G/G)
Kell KEL*01/KEL*02 KEL*01/KEL*02 (578T/C)
KEL*01/KEL*01 KEL*01/KEL*01 (578T/T)
KEL*02/KEL*02 KEL*02/KEL*02 (578C/C)
Additional polymorphisms:
KEL c. 841C>T (genotypes C/C; C/T; 
T/T)
KEL c. 1790T>C (genotypes T/T; C/T; 
C/C)
Duffy FY*01/FY*02 FY*01/FY*02 (125G/A)
FY*01/FY*01(125G/G)
FY*02/FY*02 FY*02/FY*02 (125A/A)
FY*02N.01/FY*02N.01 FY*02N.01/FY*02N.01 (─67T/T)
FY*01/FY*02N.01 (─67T/C)
Additional polymorphisms:
FY c. 265C>T (genotypes C/C; C/T)
Kidd JK*01/JK*02 JK*01/JK*02 (838G/A)
JK*01/JK*01 JK *01/JK*01 (838A/A)
JK*02/JK*02 JK *02/JK*02 (838G/G)
Dombrock DO*01/DO*02 (793A/G)
DO*01/DO*01 (793A/A)
DO*02/DO*02 DO*02/DO*02 (793G/G)
Additional polymorphisms:
DO c. 323G>T (genotypes G/G; G/T)
DO c. 350C>T (genotype C/C; C/T; 
T/T)
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used by the collaborators were PCR-SSP, either single- or multiplex, the HEA (human 
erythrocyte antigen), RHD, and RHCE BeadChip arrays from Immucor, Sanger 
sequencing, PCR-RFLP, and real-time PCR based assays. Less common methods 
included ID-CORE XT and BLOODchip REFERENCE by Progenika, MALDI-TOF-
based assays such as Hemo ID from Agena Bioscience, NGS, RBC-Ready Gene and 
Blood group system WHO IRR [98] CBER RR [89]
MNS GYPA*M/GYPA*M GYPA*M/GYPA*M (59C/C)
GYPA*M/GYPA*N GYPA*M/GYPA*N (59C/T)
GYPA*N/GYPA*N GYPA*N/GYPA*N (59 T/T)
GYPB*S/GYPB*S (143 T/T)
GYPB*S/GYPB*s GYPB*S/GYPB*s (143C/T)
GYPB*s/GYPB*s GYPB*s/GYPB*s (143C/C)
Additional polymorphisms:
GYPB c. 230C>T (genotype C/C)
GYPB c. 270+5G>T (genotype G/G)
Notes: Additional polymorphisms and genotypes included in the CBER panel are in bold; in parentheses are genotypes 
represented in the CBER panel members; descriptions of the polymorphism positions/genotypes are not available for 
WHO panel. For additional details see references [89, 98].
Table 4. 
Alleles or genotypes included in the WHO IRR and CBER RR for the overlapping blood group systems.
Blood group system Gene Polymorphism Genotypes included
ABO ABO c.1061delC CC; C/delC
c.526C>G C/C; G/C
c.703G>A G/G; G/A
c.796C>A C/C; C/A
c.803G>C G/G; G/C
c.261delG G/G; G/delG, delG/delG
Lutheran BCAM c.230G>A A/A; G/A; G/G
Diego SLC4A1 c.2561C>T C/T; C/C
Cartwright ACHE c.1057C>A C/C; C/A; A/A
Scianna ERMAP c.169G>A G/G; G/A
Colton AQP1 c.134C>T C/C; C/T; T/T
Landsteiner-Wiener ICAM4 c.299A>G A/A; A/G
Cromer CD55 c.679G>C G/G; G/C
Knops CR1 c.4681G>A G/G; G/A
c.4768A>G A/A; A/G
c.4801A>G A/A; A/G; G/G
Indian CD44 c.137G>C G/G
OK BSG c.274G>A G/G
For additional details, see reference [89].
Table 5. 
Genotypes from additional blood group systems covered by the CBER panel members.
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6. Conclusions
Alloimmunization remains a major risk for transfusion-dependent patients for 
whom transfusion is critical for survival. The transfusion management of patients 
who have already been alloimmunized is still a challenge when rare blood types are 
involved, but for new patients there is a hope that genotyping will help minimize 
exposure, except for those very rare alleles which are hard to find. One approach 
to overcome this limitation is to create a database for rare and very rare RBC alleles 
where donor selection is based on genotyping and the donor pool is constantly 
enhanced and updated. The use of RBC genotyping for both rare donor selection 
and patient care is path forward in transfusion therapy and transfusion safety. The 
development of new assays and high throughput platforms will enable mass-scale 
genotyping at lower cost and rapid pace to select rare and very rare donors. The 
development and availability of reference reagents will allow better quality control 
in assay development and evaluation of performance and proficiency of testing by 
specialized laboratories making patient care easier and safer to provide.
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